Faculty Collaboration Database

Todd W. Miller PhD

Professor

Institution: Medical College of Wisconsin
Department: Pharmacology and Toxicology

image of /images/ORCIDiD_icon16x16.png https://orcid.org/0000-0001-8912-2909

Member of the Cancer Center

I am willing to collaborate on research projects.

Send Message

Request Meeting

Publications (78)

Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer. (Tau S, Chamberlin MD, Yang H, Marotti JD, Muskus PC, Roberts AM, Carmichael MM, Cressey L, Dragnev CPC, Demidenko E, Hampsch RA, Soucy SM, Kolling FW, Samkoe KS, Alvarez JV, Kettenbach AN, Miller TW) Cancer Res 2025 Mar 14;85(6):1145-1161 PMID: 39777474 PMCID: PMC11908958 SCOPUS ID: 2-s2.0-105001220273 01/09/2025 7 Citations

Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple-negative breast cancer. (Chen Y, Salas LA, Marotti JD, Jenkins NP, Cheng C, Miller TW, Kettenbach AN, Christensen BC) Int J Cancer 2025 Mar 15;156(6):1191-1202 PMID: 39635770 PMCID: PMC11738659 SCOPUS ID: 2-s2.0-85210953201 12/05/2024 5 Citations

Pharmacological induction of chromatin remodeling drives chemosensitization in triple-negative breast cancer. (Bagheri M, Mohamed GA, Mohamed Saleem MA, Ognjenovic NB, Lu H, Kolling FW, Wilkins OM, Das S, LaCroix IS, Nagaraj SH, Muller KE, Gerber SA, Miller TW, Pattabiraman DR) Cell Rep Med 2024 Apr 16;5(4):101504 PMID: 38593809 PMCID: PMC11031425 SCOPUS ID: 2-s2.0-85189952018 04/10/2024 13 Citations

TRIM33 Is a Co-Regulator of Estrogen Receptor Alpha. (Romo BA, Karakyriakou B, Cressey L, Brauer BL, Yang H, Warren A, Johnson AL, Kettenbach AN, Miller TW) Cancers (Basel) 2024 Feb 20;16(5) PMID: 38473207 PMCID: PMC10930732 SCOPUS ID: 2-s2.0-85187699186 03/13/2024 1 Citation

Alteration of DNA methyltransferases by eribulin elicits broad DNA methylation changes with potential therapeutic implications for triple-negative breast cancer. (Bagheri M, Lee MK, Muller KE, Miller TW, Pattabiraman DR, Christensen BC) Epigenomics 2024 Mar;16(5):293-308 PMID: 38356412 PMCID: PMC10910603 SCOPUS ID: 2-s2.0-85185729042 02/15/2024 4 Citations

Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer. (Traphagen NA, Schwartz GN, Tau S, Roberts AM, Jiang A, Hosford SR, Marotti JD, Goen AE, Romo BA, Johnson AL, Duffy EK, Demidenko E, Heverly P, Mosesson Y, Soucy SM, Kolling F, Miller TW) Clin Cancer Res 2023 Sep 15;29(18):3717-3728 PMID: 37439680 PMCID: PMC10528687 SCOPUS ID: 2-s2.0-85168258598 07/13/2023 12 Citations

Alteration of DNMT1/DNMT3A by eribulin elicits global DNA methylation changes with potential therapeutic implications for triple-negative breast cancer. (Bagheri M, Lee MK, Muller KE, Miller TW, Pattabiraman DR, Christensen BC) bioRxiv 2023 Jun 10 PMID: 37333096 PMCID: PMC10274899 06/19/2023

Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer. (Schwartz GN, Kaufman PA, Giridhar KV, Marotti JD, Chamberlin MD, Arrick BA, Makari-Judson G, Goetz MP, Soucy SM, Kolling F, Demidenko E, Miller TW) Clin Cancer Res 2023 Aug 01;29(15):2767-2773 PMID: 37260292 PMCID: PMC10688025 SCOPUS ID: 2-s2.0-85166385456 06/01/2023 6 Citations

Pharmacological Induction of mesenchymal-epithelial transition chemosensitizes breast cancer cells and prevents metastatic progression. (Bagheri M, Aisha Mohamed G, Mohamed Saleem MA, Ognjenovic NB, Lu H, Kolling FW, Wilkins OM, Das S, La Croix IS, Nagaraj SH, Muller KE, Gerber SA, Miller TW, Pattabiraman DR) bioRxiv 2023 Apr 21 PMID: 37131809 PMCID: PMC10153261 05/03/2023

Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancer. (Traphagen NA, Schwartz GN, Tau S, Jiang A, Hosford SR, Goen AE, Roberts AM, Romo BA, Johnson AL, Duffy EK, Demidenko E, Heverly P, Mosesson Y, Soucy SM, Kolling F, Miller TW) bioRxiv 2023 Mar 17 PMID: 36993590 PMCID: PMC10055145 03/31/2023

The role of cancer cell bioenergetics in dormancy and drug resistance. (Tau S, Miller TW) Cancer Metastasis Rev 2023 Mar;42(1):87-98 PMID: 36696004 PMCID: PMC10233409 SCOPUS ID: 2-s2.0-85146873515 01/26/2023 15 Citations

Alpelisib Efficacy without Cherry-PI3King Mutations. (Tau S, Miller TW) Clin Cancer Res 2023 Mar 14;29(6):989-990 PMID: 36626159 PMCID: PMC10023365 SCOPUS ID: 2-s2.0-85150225933 01/11/2023 2 Citations

Tumour, whole-blood, plasma and tissue concentrations of metformin in lung cancer patients. (Phillips JD, Pooler DB, Ness DB, Fay K, Tau S, Demidenko E, Hampsch RA, Lewis LD, Miller TW) Br J Clin Pharmacol 2023 Mar;89(3):1027-1035 PMID: 36164710 PMCID: PMC9931625 SCOPUS ID: 2-s2.0-85139674325 09/28/2022 9 Citations

High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer. (Traphagen NA, Hosford SR, Jiang A, Marotti JD, Brauer BL, Demidenko E, Miller TW) Oncogene 2021 May;40(19):3408-3421 PMID: 33875787 PMCID: PMC8122072 SCOPUS ID: 2-s2.0-85104865418 04/21/2021 18 Citations

Pan-Cancer Transcriptional Models Predicting Chemosensitivity in Human Tumors. (Wells JD, Griffin JR, Miller TW) Cancer Inform 2021;20:11769351211002494 PMID: 33795931 PMCID: PMC7983245 SCOPUS ID: 2-s2.0-85102774905 04/03/2021

Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant. (Schwartz G, Shee K, Romo B, Marotti J, Kisselev A, Lewis L, Miller T) Oncologist 2021 Jun;26(6):467-e924 PMID: 33641211 PMCID: PMC8176977 SCOPUS ID: 2-s2.0-85103048467 03/01/2021 8 Citations

Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. (Axelrod ML, Nixon MJ, Gonzalez-Ericsson PI, Bergman RE, Pilkinton MA, McDonnell WJ, Sanchez V, Opalenik SR, Loi S, Zhou J, Mackay S, Rexer BN, Abramson VG, Jansen VM, Mallal S, Donaldson J, Tolaney SM, Krop IE, Garrido-Castro AC, Marotti JD, Shee K, Miller TW, Sanders ME, Mayer IA, Salgado R, Balko JM) Clin Cancer Res 2020 Nov 01;26(21):5668-5681 PMID: 32826327 PMCID: PMC7642197 SCOPUS ID: 2-s2.0-85098286523 08/23/2020 48 Citations

Identification of Let-7f-5p as a novel biomarker of recurrence in non-muscle invasive bladder cancer. (Shee K, Seigne JD, Karagas MR, Marsit CJ, Hinds JW, Schned AR, Pettus JR, Armstrong DA, Miller TW, Andrew AS) Cancer Biomark 2020;29(1):101-110 PMID: 32623385 SCOPUS ID: 2-s2.0-85092679922 07/06/2020 11 Citations

Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board. (Bernhardt EB, Chamberlin MD, Gorlov IP, de Abreu FB, Bloch KJ, Peterson JD, Tsongalis GJ, Shirai K, Dragnev KH, Miller TW, Tafe LJ) Pract Lab Med 2020 Aug;21:e00174 PMID: 32613070 PMCID: PMC7322356 SCOPUS ID: 2-s2.0-85086649224 07/03/2020 5 Citations

Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer. (Chamberlin MD, Wells JD, Shee K, Bean JR, Marotti JD, Wells WA, Trask HW, Kolling FW, Bhatt A, Kaufman PA, Schwartz GN, Gemery JM, McNulty NJ, Tsapakos MJ, Barth RJ, Arrick BA, Gui J, Miller TW) Breast Cancer Res Treat 2020 Aug;182(3):665-677 PMID: 32562118 PMCID: PMC7375191 SCOPUS ID: 2-s2.0-85086776242 06/21/2020 1 Citation

AMPK Activation by Metformin Promotes Survival of Dormant ER⁺ Breast Cancer Cells. (Hampsch RA, Wells JD, Traphagen NA, McCleery CF, Fields JL, Shee K, Dillon LM, Pooler DB, Lewis LD, Demidenko E, Huang YH, Marotti JD, Goen AE, Kinlaw WB, Miller TW) Clin Cancer Res 2020 Jul 15;26(14):3707-3719 PMID: 32321715 PMCID: PMC7367755 SCOPUS ID: 2-s2.0-85086777052 04/24/2020 86 Citations

Endocytosis of very low-density lipoproteins: an unexpected mechanism for lipid acquisition by breast cancer cells. (Lupien LE, Bloch K, Dehairs J, Traphagen NA, Feng WW, Davis WL, Dennis T, Swinnen JV, Wells WA, Smits NC, Kuemmerle NB, Miller TW, Kinlaw WB) J Lipid Res 2020 Feb;61(2):205-218 PMID: 31806729 PMCID: PMC6997602 SCOPUS ID: 2-s2.0-85078869926 12/07/2019 35 Citations

Statistical determination of synergy based on Bliss definition of drugs independence. (Demidenko E, Miller TW) PLoS One 2019;14(11):e0224137 PMID: 31765385 PMCID: PMC6876842 SCOPUS ID: 2-s2.0-85075516703 11/26/2019 114 Citations

Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy. (Shee K, Wells JD, Jiang A, Miller TW) PLoS One 2019;14(11):e0224267 PMID: 31682620 PMCID: PMC6827986 SCOPUS ID: 2-s2.0-85074351791 11/05/2019 39 Citations

A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition. (Shee K, Wells JD, Ung M, Hampsch RA, Traphagen NA, Yang W, Liu SC, Zeldenrust MA, Wang L, Kalari KR, Yu J, Boughey JC, Demidenko E, Kettenbach AN, Cheng C, Goetz MP, Miller TW) Clin Cancer Res 2020 Jan 01;26(1):159-170 PMID: 31558472 PMCID: PMC6942625 SCOPUS ID: 2-s2.0-85077477995 09/29/2019 1 Citation

Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma. (Miller TW, Traphagen NA, Li J, Lewis LD, Lopes B, Asthagiri A, Loomba J, De Jong J, Schiff D, Patel SH, Purow BW, Fadul CE) J Neurooncol 2019 Sep;144(3):563-572 PMID: 31399936 PMCID: PMC6863163 SCOPUS ID: 2-s2.0-85070279150 08/11/2019 41 Citations

Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer. (Hosford SR, Shee K, Wells JD, Traphagen NA, Fields JL, Hampsch RA, Kettenbach AN, Demidenko E, Miller TW) Mol Oncol 2019 Aug;13(8):1778-1794 PMID: 31180176 PMCID: PMC6670014 SCOPUS ID: 2-s2.0-85068649142 06/11/2019 17 Citations

Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier. (Chen Y, Wang Y, Salas LA, Miller TW, Mark K, Marotti JD, Kettenbach AN, Cheng C, Christensen BC) Breast Cancer Res 2019 Jan 25;21(1):14 PMID: 30683142 PMCID: PMC6347811 SCOPUS ID: 2-s2.0-85060518440 01/27/2019 12 Citations

Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing. (Shee K, Muller KE, Marotti J, Miller TW, Wells WA, Tsongalis GJ) Am J Pathol 2019 May;189(5):956-965 PMID: 30385093 PMCID: PMC6521891 SCOPUS ID: 2-s2.0-85064541749 11/06/2018 23 Citations

Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER⁺ breast cancer. (Shee K, Jiang A, Varn FS, Liu S, Traphagen NA, Owens P, Ma CX, Hoog J, Cheng C, Golub TR, Straussman R, Miller TW) FASEB J 2019 Feb;33(2):1644-1657 PMID: 30161001 PMCID: PMC6338642 SCOPUS ID: 2-s2.0-85060955191 08/31/2018 16 Citations

Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer. (Yang W, Schwartz GN, Marotti JD, Chen V, Traphagen NA, Gui J, Miller TW) Oncotarget 2018 Feb 06;9(10):8810-8822 PMID: 29507656 PMCID: PMC5823630 SCOPUS ID: 2-s2.0-85041378939 03/07/2018 17 Citations

Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. (Floros KV, Lochmann TL, Hu B, Monterrubio C, Hughes MT, Wells JD, Morales CB, Ghotra MS, Costa C, Souers AJ, Boikos SA, Leverson JD, Tan M, Serra V, Koblinski JE, Arribas J, Prat A, Paré L, Miller TW, Dozmorov MG, Harada H, Windle BE, Scaltriti M, Faber AC) Proc Natl Acad Sci U S A 2018 Mar 13;115(11):E2594-E2603 PMID: 29476008 PMCID: PMC5856537 SCOPUS ID: 2-s2.0-85043771254 02/25/2018 30 Citations

Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. (Shee K, Yang W, Hinds JW, Hampsch RA, Varn FS, Traphagen NA, Patel K, Cheng C, Jenkins NP, Kettenbach AN, Demidenko E, Owens P, Faber AC, Golub TR, Straussman R, Miller TW) J Exp Med 2018 Mar 05;215(3):895-910 PMID: 29436393 PMCID: PMC5839765 SCOPUS ID: 2-s2.0-85042874734 02/14/2018 69 Citations

Trailblazing Precision Oncology for Rare Tumor Subtypes. (Shee K, Miller TW) Oncologist 2018 Feb;23(2):143-144 PMID: 29158369 PMCID: PMC5813755 SCOPUS ID: 2-s2.0-85042109587 11/22/2017

Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer. (Yang W, Hosford SR, Traphagen NA, Shee K, Demidenko E, Liu S, Miller TW) FASEB J 2018 Mar;32(3):1222-1235 PMID: 29127189 PMCID: PMC5892720 SCOPUS ID: 2-s2.0-85043513684 11/12/2017 27 Citations

P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site. (Marotti JD, Muller KE, Tafe LJ, Demidenko E, Miller TW) Int J Breast Cancer 2017;2017:4537532 PMID: 28698809 PMCID: PMC5494073 SCOPUS ID: 2-s2.0-85021647805 07/13/2017 11 Citations

Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer. (Hampsch RA, Shee K, Bates D, Lewis LD, Désiré L, Leblond B, Demidenko E, Stefan K, Huang YH, Miller TW) Oncotarget 2017 Mar 28;8(13):21806-21817 PMID: 28423521 PMCID: PMC5400625 SCOPUS ID: 2-s2.0-85016430871 04/21/2017 33 Citations

Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin. (Shee K, Kono AT, D'Anna SP, Seltzer MA, Lu X, Miller TW, Chamberlin MD) Case Rep Oncol 2016;9(3):840-846 PMID: 28101033 PMCID: PMC5216250 SCOPUS ID: 2-s2.0-85009726492 01/20/2017 6 Citations

Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER⁺ Breast Cancer. (Hosford SR, Dillon LM, Bouley SJ, Rosati R, Yang W, Chen VS, Demidenko E, Morra RP Jr, Miller TW) Clin Cancer Res 2017 Jun 01;23(11):2795-2805 PMID: 27903677 PMCID: PMC5449270 SCOPUS ID: 2-s2.0-85020241153 12/03/2016 27 Citations

Application of RNAi-induced gene expression profiles for prognostic prediction in breast cancer. (Wang Y, Mark KM, Ung MH, Kettenbach A, Miller T, Xu W, Cheng W, Xia T, Cheng C) Genome Med 2016 Oct 27;8(1):114 PMID: 27788678 PMCID: PMC5084341 SCOPUS ID: 2-s2.0-84992560051 10/30/2016 3 Citations

The PREX1/Rac signaling axis: Potential as a biomarker and therapeutic target in breast cancer. (Dillon LM, Miller TW) Mol Cell Oncol 2015;2(3):e996016 PMID: 27308485 PMCID: PMC4905322 SCOPUS ID: 2-s2.0-85031397650 06/17/2016 6 Citations

Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer. (Chamberlin MD, Bernhardt EB, Miller TW) J Cell Biochem 2016 Nov;117(11):2454-63 PMID: 27146558 PMCID: PMC6010350 SCOPUS ID: 2-s2.0-84986192023 05/06/2016 12 Citations

Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers. (Muller KE, Marotti JD, de Abreu FB, Peterson JD, Miller TW, Chamberlin MD, Tsongalis GJ, Tafe LJ) Exp Mol Pathol 2016 Jun;100(3):421-5 PMID: 27095739 SCOPUS ID: 2-s2.0-84964336618 04/21/2016 29 Citations

Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer. (Yang W, Hosford SR, Dillon LM, Shee K, Liu SC, Bean JR, Salphati L, Pang J, Zhang X, Nannini MA, Demidenko E, Bates D, Lewis LD, Marotti JD, Eastman AR, Miller TW) Clin Cancer Res 2016 May 01;22(9):2250-60 PMID: 26733612 PMCID: PMC4854767 SCOPUS ID: 2-s2.0-84968538982 01/07/2016 29 Citations

Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center. (Tafe LJ, Gorlov IP, de Abreu FB, Lefferts JA, Liu X, Pettus JR, Marotti JD, Bloch KJ, Memoli VA, Suriawinata AA, Dragnev KH, Fadul CE, Schwartz GN, Morgan CR, Holderness BM, Peterson JD, Tsongalis GJ, Miller TW, Chamberlin MD) Oncologist 2015 Sep;20(9):1011-8 PMID: 26205736 PMCID: PMC4571816 SCOPUS ID: 2-s2.0-84940654294 07/25/2015 79 Citations

The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. (Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, Shee K, Schwartz GN, Marotti JD, Muller KE, Rosenkranz KM, Barth RJ, Chen VS, Agarwal VR, Miller TW) Breast Cancer Res Treat 2015 Jan;149(1):69-79 PMID: 25491778 PMCID: PMC4302040 SCOPUS ID: 2-s2.0-84925517350 12/11/2014 14 Citations

Estrogen receptor alpha and androgen receptor are commonly expressed in well-differentiated liposarcoma. (Ingram DR, Dillon LM, Lev DC, Lazar A, Demicco EG, Eisenberg BL, Miller TW) BMC Clin Pathol 2014;14:42 PMID: 25349530 PMCID: PMC4209467 SCOPUS ID: 2-s2.0-84988603083 10/29/2014 13 Citations

P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. (Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW) Oncogene 2015 Jul 23;34(30):3968-76 PMID: 25284585 PMCID: PMC4387124 SCOPUS ID: 2-s2.0-84937967918 10/07/2014 73 Citations

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. (Hosford SR, Miller TW) Pharmgenomics Pers Med 2014;7:203-15 PMID: 25206307 PMCID: PMC4157397 SCOPUS ID: 2-s2.0-84905663688 09/11/2014 145 Citations

Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. (Liu S, Meng X, Chen H, Liu W, Miller T, Murph M, Lu Y, Zhang F, Gagea M, Arteaga CL, Mills GB, Meric-Bernstam F, González-Angulo AM) Oncotarget 2014 Oct 15;5(19):9049-64 PMID: 24979294 PMCID: PMC4253418 SCOPUS ID: 2-s2.0-84910029848 07/01/2014 23 Citations

Therapeutic targeting of cancers with loss of PTEN function. (Dillon LM, Miller TW) Curr Drug Targets 2014 Jan;15(1):65-79 PMID: 24387334 PMCID: PMC4310752 SCOPUS ID: 2-s2.0-84893003451 01/07/2014 212 Citations

Managing breast cancers with low estrogen receptor and HER2 by drugging both. (Miller TW) Clin Cancer Res 2014 Feb 01;20(3):528-30 PMID: 24352641 PMCID: PMC3946528 SCOPUS ID: 2-s2.0-84893485945 12/20/2013 2 Citations

Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. (Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gómez H, Cook RS, Arteaga CL) Cancer Res 2013 Oct 15;73(20):6346-58 PMID: 23966295 PMCID: PMC4090144 SCOPUS ID: 2-s2.0-84886046699 08/24/2013 137 Citations

Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. (Fox EM, Kuba MG, Miller TW, Davies BR, Arteaga CL) Breast Cancer Res 2013;15(4):R55 PMID: 23844554 PMCID: PMC3979036 SCOPUS ID: 2-s2.0-84880015651 07/13/2013 81 Citations

Endocrine resistance: what do we know? (Miller TW) Am Soc Clin Oncol Educ Book 2013 PMID: 23714450 SCOPUS ID: 2-s2.0-84952360331 05/30/2013 19 Citations

Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer. (Fox EM, Arteaga CL, Miller TW) Front Oncol 2012;2:145 PMID: 23087906 PMCID: PMC3472546 10/23/2012

Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. (Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F) Clin Cancer Res 2012 Oct 15;18(20):5816-28 PMID: 22932669 PMCID: PMC3772348 SCOPUS ID: 2-s2.0-84867506516 08/31/2012 144 Citations

Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification. (Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL) Mol Cancer Ther 2012 Oct;11(10):2301-5 PMID: 22879364 PMCID: PMC3682668 SCOPUS ID: 2-s2.0-84867419866 08/11/2012 21 Citations

Membrane-initiated estrogen signaling: oncogenic or impotent? (Miller TW) Expert Rev Endocrinol Metab 2012 Jul;7(4):411-413 PMID: 30754162 SCOPUS ID: 2-s2.0-84864593767 07/01/2012

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. (Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, Arteaga CL) Nat Med 2012 Jul;18(7):1052-9 PMID: 22683778 PMCID: PMC3693569 SCOPUS ID: 2-s2.0-84863726932 06/12/2012 230 Citations

Initiating breast cancer by PIK3CA mutation. (Miller TW) Breast Cancer Res 2012 Feb 07;14(1):301 PMID: 22315990 PMCID: PMC3496136 SCOPUS ID: 2-s2.0-84856774967 02/10/2012 19 Citations

The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. (Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sánchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS) Proc Natl Acad Sci U S A 2012 Jan 03;109(1):221-6 PMID: 22178756 PMCID: PMC3252958 SCOPUS ID: 2-s2.0-84856012318 12/20/2011 59 Citations

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. (Miller TW, Rexer BN, Garrett JT, Arteaga CL) Breast Cancer Res 2011;13(6):224 PMID: 22114931 PMCID: PMC3315683 SCOPUS ID: 2-s2.0-80755127903 11/26/2011 392 Citations

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. (Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, González-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL) Cancer Discov 2011 Sep;1(4):338-51 PMID: 22049316 PMCID: PMC3204388 SCOPUS ID: 2-s2.0-82055187255 11/04/2011 291 Citations

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. (Miller TW, Balko JM, Arteaga CL) J Clin Oncol 2011 Nov 20;29(33):4452-61 PMID: 22010023 PMCID: PMC3221526 SCOPUS ID: 2-s2.0-81755162797 10/20/2011 370 Citations

A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. (Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL) Cancer Res 2011 Nov 01;71(21):6773-84 PMID: 21908557 PMCID: PMC3206206 SCOPUS ID: 2-s2.0-80155131176 09/13/2011 140 Citations

Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. (Yang X, Turke AB, Qi J, Song Y, Rexer BN, Miller TW, Jänne PA, Arteaga CL, Cantley LC, Engelman JA, Asara JM) Cancer Res 2011 Sep 15;71(18):5965-75 PMID: 21775521 PMCID: PMC3209668 SCOPUS ID: 2-s2.0-80052815712 07/22/2011 15 Citations

A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. (Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, González-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL) Clin Cancer Res 2011 Apr 01;17(7):2024-34 PMID: 21346144 PMCID: PMC3221728 SCOPUS ID: 2-s2.0-79953311521 02/25/2011 90 Citations

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. (Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL) J Clin Invest 2010 Jul;120(7):2406-13 PMID: 20530877 PMCID: PMC2898598 SCOPUS ID: 2-s2.0-77954974573 06/10/2010 482 Citations

Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. (Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A, Cook RS, Kennedy JP, Lindsley CW, Arteaga CL) Clin Cancer Res 2009 Dec 01;15(23):7266-76 PMID: 19934303 PMCID: PMC2787848 SCOPUS ID: 2-s2.0-73149101585 11/26/2009 115 Citations

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. (Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, Nolting DD, Buck JR, Zhao P, Ansari MS, Baldwin RM, Gore JC, Schiff R, Arteaga CL, Manning HC) Clin Cancer Res 2009 Jul 15;15(14):4712-21 PMID: 19584166 PMCID: PMC2819132 SCOPUS ID: 2-s2.0-68049090042 07/09/2009 78 Citations

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. (Miller TW, Pérez-Torres M, Narasanna A, Guix M, Stål O, Pérez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, Lindsley CW, Arteaga CL) Cancer Res 2009 May 15;69(10):4192-201 PMID: 19435893 PMCID: PMC2724871 SCOPUS ID: 2-s2.0-66249119060 05/14/2009 158 Citations

Aromatase is phosphorylated in situ at serine-118. (Miller TW, Shin I, Kagawa N, Evans DB, Waterman MR, Arteaga CL) J Steroid Biochem Mol Biol 2008 Nov;112(1-3):95-101 PMID: 18822378 PMCID: PMC2856845 SCOPUS ID: 2-s2.0-55349119474 09/30/2008 45 Citations

ErbB receptor signaling and therapeutic resistance to aromatase inhibitors. (Shin I, Miller T, Arteaga CL) Clin Cancer Res 2006 Feb 01;12(3 Pt 2):1008s-1012s PMID: 16467117 SCOPUS ID: 2-s2.0-32944476929 02/10/2006 43 Citations

Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. (Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, Messer A) Proc Natl Acad Sci U S A 2005 Aug 09;102(32):11563-8 PMID: 16061794 PMCID: PMC1183604 SCOPUS ID: 2-s2.0-23844543718 08/03/2005 135 Citations

Intrabody applications in neurological disorders: progress and future prospects. (Miller TW, Messer A) Mol Ther 2005 Sep;12(3):394-401 PMID: 15964243 SCOPUS ID: 2-s2.0-23844450357 06/21/2005 76 Citations

A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease. (Miller TW, Zhou C, Gines S, MacDonald ME, Mazarakis ND, Bates GP, Huston JS, Messer A) Neurobiol Dis 2005;19(1-2):47-56 PMID: 15837560 SCOPUS ID: 2-s2.0-17544377783 04/20/2005 52 Citations

DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype. (Miller TW, Shirley TL, Wolfgang WJ, Kang X, Messer A) Mol Ther 2003 May;7(5 Pt 1):572-9 PMID: 12718899 SCOPUS ID: 2-s2.0-0037562002 04/30/2003 57 Citations

Last update: 08/12/2025

© 2026 Clinical & Translational Science Institute
Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53223

Publication and ontology data from NCBI | Disclaimer and Copyright

This site is a collaborative effort of the Medical College of Wisconsin and the Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number 2UL1TR001436) at the National Institutes of Health (NIH).

Profiles for MCW, MU, MSOE, UWM, BCW, CW, Froedtert, and VA Faculty

Todd W. Miller PhD

Professor

Publications (78)